Introduction
Periodic paralysis was first described in 1874 by Hartwig. 1 In Western countries, most cases of hypokalaemic paralysis are due to familial hypokalaemic periodic paralysis. 2 However, in Hong Kong, where 97% of the population are Chinese, the commonest cause is thyrotoxic periodic paralysis (TPP). 3 Association between thyrotoxicosis and periodic paralysis was first reported by Rosenfeld in 1902. 4 Mortality and significant morbidity associated with TPP, though uncommon, have been reported. 5 " 11 We performed a retrospective study of adult patients admitted with hypokalaemic paralysis into a regional general hospital. We found that 45/56 patients (80.4%) were thyrotoxic. We describe the clinical characteristics of these 45 patients and review the findings with reference to previous publications.
Methods

Patients
Our data come from patients registered between 1984 and 1993. All were adults requiring emergency admission with varying degrees of limb weakness. At presentation, all had plasma potassium 3.5 mmol/l. Their hospital notes were studied retrospectively. Only patients with unequivocal biochemical evidence of thyrotoxicosis are reported.
Biochemical thyrotoxicosis was defined as total T4>140nmol/I (normal and/or free T4>21.8pmol/I (normal 10.2-21.8) (before 1990) or thyroid-stimulating hormone (TSH) <0.03 mlU/l (normal 0.3-4) and free T4 >21.8pmol/l (1990 or after).
Analytical methods
Thyroid-stimulating hormone was measured by the TSH double-antibody RIA test (Diagnostic Products) prior to November 1989, and subsequently by a sensitive immunometric assay (ICMA-TSH assay: Magic Lite, Ciba-Cornings). Total T4 (EMIT ACA thyroxine assay system, Syva) was used until November 1989, while free T3 (Amerlex-M free T3 RIA Kit: Amersham) and free T4 (two-step coatedtube RIA: Baxter Healthcare) became available in early 1988. The inter-assay coefficients of variation were < 1 2 % . Erythrocyte zinc concentrations (RBCZn) were measured by atomic absorption spectrophotometry as described previously. 12 The coefficients of variation between assays were 5%. The normal range in our laboratory is 155-231 umol/l red cells. Thyroid anti-thyroglobulin and anti-microsomal antibodies were measured by passive haemagglutination using Thymune-M and Thymune-T kits (Wellcome Reagents). Titers ^1 : 2 0 and 1:400, respectively, were considered positive.
Statistical analysis
All data were expressed as means+ SEM. Correlation between plasma potassium level on admission, thyroid function test and other clinical parameters were tested by Spearman's least square analysis with p < 0 . 0 5 as significant.
Results
There were 78 admissions due to hypokalaemic paralysis. Detailed and accurate information was obtained in relation to 73 of these (93.6%), and 55 were judged due to TPP (75.3%). Fifty-six patients accounted for the 73 admissions (some had more than one admission), of whom 45 were diagnosed as TPP (80.4%). Thus 45 TPP patients had 55 admissions. Six patients (13.3%) were admitted twice, while two patients (4.4%) had three admissions.
The Prince of Wales Hospital provides a service to the New Territories East district of Hong Kong with a population of approximately 1 million in 1992. Thus the approximate incidence of TPP in Hong Kong is estimated to be 4.5 patients per million per year.
Of the 45 patients, 44 were male and one was female. All were ethnic Chinese. The mean age was 33.4 + 1.0 years (range 22-55). In most patients, the onset of paralysis occurred either late in the evening or early in the morning. Seventy-five percent of attacks developed between 9pm and 9am, with two peaks, one at 9pm to 12 midnight (26.9%) and another at 3am to 9am (32.7%). Attacks occurred most commonly in August (20%), and 49% occurred between July and October during the hottest time of year in Hong Kong.
We have graded the severity of paralysis into three categories: mild weakness, whereby patients could still walk without assistance; moderate weakness, whereby assistance to walk was needed; and total paralysis. Most TPP patients (74.6%) were admitted with total paralysis. Only 1.8% were admitted with mild weakness and 23.6% with moderate weakness.
Plasma potassium concentrations on admission ranged from 1.1 to 3.5 mmol/l (mean 2.17 + 0.08) ( Figure 1 ). Intravenous potassium requirements prior to recovery ranged from zero to 230 mmol (mean 73.2+7.5). A few received oral potassium supplements only (26.8-162 .0 mmol, mean 103.2 + 5.6). Upon recovery, peak plasma potassium concentrations ranged from 3.6 to 7.2 mmol/l (mean 4.7 + 0.12) ( Table 1 ). In 15 cases (27.3%), potassium on recovery transiently exceeded 5 mmol/l, while in three (5.5%), 6 mmol/l was exceeded.
Exercise and high carbohydrate loads are wellknown precipitating factors for TPP. 7.3% of our patients had exercise followed by rest before the onset of paralysis. Heavy meals or sweet snacks were recognized as precipitating factors in 23.6%.
No patient had a positive family history of TPP, although seven patients (17.8%) had a family history of thyrotoxicosis in one or more family members. Twenty-nine (64.4%) gave a prior history of thyrotoxic symptoms before TPP attacks and 27 (60%) were clinically thyrotoxic at presentation. Goiter was present in 27 but none had significant infiltrative ophthalmopathy. Two (4.4%) had previously undergone partial thyroidectomy (3 and 13 years before TPP attacks) and in both, relapse of thyrotoxicosis occurred before their paralytic attacks.
The results of thyroid function tests were as follows: for those who were diagnosed to be thyrotoxic before 1990, all had total T4>140nmol/I and/or free T4>21.8 pmol/l. For those who were diagnosed to be thyrotoxic after 1990, all had TSH <0.03 mlU/l and free T4>21.8 pmol/l. In most patients (88.6%) free T3 exceeded 8.2 pmol/l (normal 3.3-8.2). RBC Zn was < 155 u.mol/1 red cells (normal 155-237) in 75% of those in whom it was measured (n = 26). Positive thyroid anti-microsomal and/or antithyroglobulin antibodies were recorded in 66% of patients.
Of the 55 admissions, eight (14.6%) were incorrectly diagnosed at presentation. Misdiagnoses included Guillain-Barre syndrome, acute spinal cord compression, myelitis and hysteria.
Discussion
Epidemiology and clinical presentation
The incidence of TPP in the West is uncertain. Our data from Hong Kong indicate an incidence of approximately 4.5 patients per million per year. The figure is almost certainly an underestimate, because individuals with mild attacks may not require admission and those with normokalaemia have been excluded from this analysis. Our incidence of admissions due to TPP is 5.5 per million per year.
TPP is known to occur predominantly among Asians, although it has also been reported in Hispanics, 13 19 and administration of exogenous thyroid hormone. 27 In our study, Graves' disease was by far the commonest cause, and this reflects the pattern of thyroid disease in the Hong Kong community. The severity of hyperthyroidism correlates poorly with TPP attacks. There are recent reports showing that the hyperthyroidism is 'clinically silent' in some cases. 16 In our study, more than one-tenth (11.4%) had relatively mild thyrotoxicosis (suppressed thyroid-stimulating hormone, high free thyroxine but normal free triiodothyronine). 28 Interestingly, 25% of our patients had normal RBC Zn. We have previously reported that RBC Zn concentration reflects the integrated functional state of the thyroid over the preceding 2 to 3 months in a manner similar to glycosylated haemoglobin in diabetic patients. 29 This has been confirmed by other studies. 30 ' 31 The normal RBC Zn in 25% of our patients therefore signifies recent onset of thyrotoxicosis. Thus TPP may be an early manifestation of thyrotoxicosis, the severity of the symptom leading to earlier diagnosis in vulnerable patients.
Pathophysiology
HLA markers have been extensively studied. HLA A2, Bw22, Aw19 and B17 have been reported to be more common in TPP patients in Singapore and Thailand. 23 ' 24 ' 32 In Caucasians, the disease is associated with HLA DR3. 33 In our population, the prevalence of Bw46 has been reported to be increased in patients with TPP. 34 We also found a weak association of HLA B46, DR9 and DQB1*O3O3 in Hong Kong Chinese males with TPP. 35 Thyroid hormone can increase Na,K-ATPase activity in skeletal muscle, liver and kidney 36 
Treatment
Numerous drugs have been used in attempts to prevent TPP. Reserpine may alleviate most sympathetic manifestations of thyrotoxicosis, but fails to prevent TPP. 41 Acetazolamide has been studied in patients with hypokalaemic periodic paralysis and has been claimed to be the most effective agent in preventing paralytic episodes. 42 However, it is inconclusive in TPP, both success and failure having been reported with acetazolamide as a prophylactic propranolol and propylthiouracil to establish rapid control of the thyrotoxicosis, followed by ablative radioactive iodine therapy in the majority of cases.
Conclusions
Hypokalaemic paralysis is not uncommon in Hong 
